Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on prostate cancer therapies, reported its financial results for the second fiscal quarter ending March 31, 2024. Highlights include the promising Phase 1 data for masofaniten plus enzalutamide, showing a deep and durable reduction in PSA levels among mCRPC patients. Key achievements include 81% of patients achieving PSA90. ESSA forecasts the completion of Phase 2 enrollment by 1Q25, with preliminary data expected in mid-2025. Financially, ESSA experienced a net loss of $9.0 million, up from $7.1 million the previous year, due to increased R&D and G&A expenses. The company holds $135.9 million in cash reserves, enough to fund operations beyond 2025.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
